PreOmics

About

PreOmics is a company that develops and produces innovative technologies for the pre-analytics of samples for mass spectrometry.

Martinsried,Bayern,Germany
11 - 50

Highlights

Details

Last Funding Type: Series A
Last Funding Money Raised: €3.30M
Industries: Analytics,Biotechnology,Productivity Tools
Founded date: Aug 1, 2016
Number Of Employee: 11 - 50
Operating Status: Active
Legal Name: PreOmics GmbH

PreOmics develops and provides innovative tools for customers around the world for mass spectrometry (MS)-based proteomics using cutting-edge technologies to support researchers in their protein analysis needs.

PreOmics is as a spin-off company from the proteomics research group of pioneer Matthias Mann at the Max-Planck Institute of Biochemistry. They at PreOmics develop and provide innovative technologies for mass spectrometry-based proteomics to make your research simply better. Their mission is to provide you with the best possible solutions and at the highest quality to achieve your results faster, easier and in a more robust manner than ever before.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

4

€16.87M

PreOmics has raised a total of €16.87M in funding over 2 rounds. Their latest funding was raised on Jan 19, 2022 from a Series B round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jan 19, 2022	Series B	€13.50M	—	—	—	Detail
Jan 1, 2019	Grant	€71.42K	1	—	—	Detail
Dec 27, 2018	Series A	€3.30M	3	Think.Health	—	Detail
Dec 27, 2018	Series A	—	1	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

1

5

PreOmics is funded by 5 investors. Think.Health and EASME - EU Executive Agency for SMEs are the most recent investors.

Investor Name	Lead Investor	Funding Round
Think.Health	Yes	Series A
EASME - EU Executive Agency for SMEs	—	Grant
business angels	—	Series A
High-Tech Grunderfonds	—	Series A
TBA Tyrolean Business Angel	—	Series A